Our results revealed that raloxifene hydrochloride, as a kind of selective estrogen receptor modulator (SERM), could help inhibit bone loss around the prosthesis and improve women's QoL after THA with no increased adverse events, as well as decrease the odds of breast cancer. The gene discussed is ESR1; the disease is breast cancer.